

# 2020 Fiscal Year and Fourth Quarter Earnings Call

February 1, 2021

## Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of federal securities laws. These forward-looking statements include statements with respect to the 2021 and 2025 targets, growth targets and other expectations and other non-historical information. Without limiting the foregoing, statements including the words, "expect," "intend," "will," "plan," "anticipate," "believe," "forecast," "guidance," "outlook," "goals," "target," estimate" and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell's control and are subject to various risks and uncertainties, including those described below. Among other things, there can be no assurance that Omnicell's actual results or growth rates will not differ, perhaps substantially, from the targets and expectations contained in this presentation.

Such statements include, but are not limited to, Omnicell's projected revenues, operating margin and EBITDA margin; planned new products and services; and statements about Omnicell's strategy, objectives and vision. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) risks related to outbreaks of contagious diseases or other adverse public health epidemics including the ongoing COVID-19 pandemic, including the duration and any resurgences of the COVID-19 pandemic, (ii) unfavorable general economic and market conditions, including due to economic disruption caused by public health crises such as the COVID-19 pandemic, (iii) Omnicell's ability to take advantage of the growth opportunities in medication management across all care settings, (iv) Omnicell's ability to develop and commercialize new products and enhance existing products, (v) Omnicell's ability to deliver on our vision of the autonomous pharmacy and the impact that advanced automation, data intelligence and expert services will have on patient care, (vi) risks to growth and acceptance of Omnicell's products and services, including competitive conversions, and growth in the overall demand for medication management and supply chain solutions and medication adherence solutions generally, (vii) risks presented by the transition to selling more products and services on a subscription basis, (viii) potential increased competition, (ix) potential regulatory changes, (x) Omnicell's ability to acquire companies, businesess or technologies and successfully integrate such acquisitions and (xii) other risks and uncertainties described in the Risk Factors section of Omnicell's most recent annual report on Form 10-K and quarterly report on Form 10-Q, filed with the United States Securities and Exchange Commission. Forward-looking statements, whether as a

### Non-GAAP Financial Information

This presentation contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"), including 2020 non-GAAP operating margin margin and targeted non-GAAP EBITDA margin. Reconciliations of the 2020 non-GAAP financial measures, as well as non-GAAP gross profit, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, non-GAAP net income per share-diluted and non-GAAP EBITDA, to the most directly comparable GAAP measures are included in the Appendix to this presentation. Our non-GAAP operating margin target, non-GAAP EBITDA margin target, non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income per share-diluted and non-GAAP EBITDA exclude certain items, which include, but are not limited to, unusual gains and losses, costs associated with future restructurings, acquisition-related expenses and certain tax and litigation outcomes. These excluded items may be significant. We do not provide a reconciliation of forward-looking non-GAAP targets to the comparable GAAP measures as these items are inherently uncertain and difficult to estimate, and cannot be predicted without unreasonable effort. We believe such a reconciliation would imply a degree of precision that could be confusing to investors. These items may also have a material impact on GAAP earnings per share, total revenues, product revenues and service revenues in future periods. As such, these forward-looking non-GAAP financial measures are limited in their utility for evaluating our future operating results in accordance with GAAP.

### Resilient and High-Visibility Revenue

Robust Backlog

#### Robust product backlog

Deep Customer Relationships ■ **145** of the top 300 U.S. health systems in long-term, sole-source agreements<sup>1,2</sup>

Customer Retention


• 99%+ customer retention<sup>3</sup>

#### Point of Care Installed Base Early in Upgrade Cycle

■ **36%** through XT series replacement cycle<sup>2</sup>

As defined by Definitive Healthcare.
As of 12/31/2020.
© 2021 Omnicell. Inc.


Measured over the past year on a revenue basis.
High revenue visibility based on backlog, pipeline & LT sole-source agreements.



 Includes Central Pharmacy Dispense Services (XR2aaS), EnlivenHealth, IV RIIS Service, Omnicell 340B, Omnicell One Service and RobotRX Service (Pak Plus).
Includes revenue from Consumables.

## Advanced Services Accelerating Recurring Revenue Growth


SaaS, Subscription Software & Tech-Enabled Services (% of Total Revenue)



- Leveraging established channel and strong customer relationships
- ✓ Strong demand driven by increasing provider digitization and need to evolve medication supply chain
- ✓ Omnicell's cloud-based services enable better outcomes
- ✓ Subscription-based, recurring revenue streams
- ✓ Significantly increases core addressable market
- $\checkmark$  High margin unit economics

# Driving Profitable Growth Through Disciplined Execution

Expected Annual Revenue (\$ in Millions)



## Continuing to Drive Margin Expansion



#### Key Drivers of Margin Enhancement

Improving Business Mix – SaaS, Subscription Software & Tech-Enabled Services targeted to represent 20-30% of revenue by 2025, supporting strong gross margins

Long-Term Customer Partnerships – Sole-source agreements with 145 of the top 300 U.S. health systems<sup>1,2</sup> and many outside of the top 300

Economies of Scale – Supply chain and operating expense volume leverage

Manufacturing Savings – Cost productivity programs

**Process Efficiencies** – Increasing virtualization of commercial and implementation processes

1. As of 12/31/2020. 2. As defined by Definitive Healthcare.

DISCLAIMER: See Appendix for a reconciliation of 2020 non-GAAP operating margin and 2020 non-GAAP EBITDA margin to their most directly comparable GAAP financial measures. We do not provide a reconciliation of forward-looking non-GAAP guidance to the comparable GAAP measures as these items are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort.

© 2021 Omnicell, In

# Appendix

#### Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage)

	Tł	ree Months Er	nded l	December 31,	2020 2019			
		2020		2019		2020		2019
Reconciliation of GAAP gross profit to non-GAAP gross	profit:							
GAAP gross profit	\$	123,654	\$	123,603	\$	413,292	\$	436,912
GAAP gross margin		49.6%		49.8%		46.3%		48.7%
Share-based compensation expense		1,811		1,454		7,469		5,648
Amortization of acquired intangibles		2,901		2,035		9,001		8,182
Severance-related expenses		_				2,564		_
Non-GAAP gross profit	\$	128,366	\$	127,092	\$	432,326	\$	450,742
Non-GAAP gross margin		51.5%		51.2%		48.5%		50.2%
Reconciliation of GAAP operating expenses to non-GAA	P operat	ing expense	s:					
GAAP operating expenses	\$	103,440	\$	101,421	\$	377,766	\$	358,560
GAAP operating expenses % to total revenues		41.5%		40.8%		42.3%		40.0%
Share-based compensation expense		(9,852)		(7,420)		(37,228)		(28,401
Amortization of acquired intangibles		(3,545)		(2,690)		(10,601)		(10,581)
Acquisition-related expenses		(2,482)		_		(5,603)		_
Severance-related and other expenses <sup>(a)</sup>		(1,113)		(795)		(9,385)		(1,715)
Non-GAAP operating expenses	\$	86,448	\$	90,516	\$	314,949	\$	317,863
Non-GAAP operating expenses % to total revenues		34.7%		36.5%		35.3%		35.4%

Reconciliation of GAAP income from operations to non-GAA	P in	come from	oper	ations:		
GAAP income from operations	\$	20,214	\$	22,182	\$ 35,526	\$ 78,352
GAAP operating income % to total revenues		8.1%		8.9%	4.0%	8.7%
Share-based compensation expense		11,663		8,874	44,697	34,049
Amortization of acquired intangibles		6,446		4,725	19,602	18,763
Acquisition-related expenses		2,482			5,603	_
Severance-related and other expenses <sup>(a)</sup>		1,113		795	 11,949	1,715
Non-GAAP income from operations	\$	41,918	\$	36,576	\$ 117,377	\$ 132,879
Non-GAAP operating margin (non-GAAP operating income % to total revenues)		16.8%		14.7%	 13.2%	14.8%

#### Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage)

	Three Months Ended December 31,				Year Ended December 31,					
	2020		2019		2020		2019			
Reconciliation of GAAP net income to non-GAAP net incom	ie:									
GAAP net income	\$	16,377	\$	22,095	\$	32,194	\$	61,338		
Tax impact of IP restructuring		_		(2,192)		—		7,432		
Share-based compensation expense		11,663		8,874		44,697		34,049		
Amortization of acquired intangibles		6,446		4,725		19,602		18,763		
Acquisition-related expenses		2,482		_		5,603		_		
Severance-related and other expenses <sup>(a)</sup>		1,113		795		11,949		1,715		
Amortization of debt issuance costs		843		486		1,597		2,205		
Amortization of discount on convertible senior notes		4,517		_		4,766		_		
Tax effect of the adjustments above (b)		(3,234)		(1,261)		(9,139)		(4,762		
Non-GAAP net income	\$	40,207	\$	33,522	\$	111,269	\$	120,740		
		_				_				
Reconciliation of GAAP net income per share- diluted to no	on-GA	AAP net inc	ome 1	oer share- o	lilute	ed:				
Shares - diluted GAAP		44,001		43,327		43,743		42,943		
Dilution offset from convertible note hedge transaction <sup>(c)</sup>		(45)	_	_		_	_	_		
Shares - diluted Non-GAAP		43,956		43,327		43,743		42,943		
						_				
GAAP net income per share- diluted	\$	0.37	\$	0.51	\$	0.74	\$	1.43		
Tax impact of IP restructuring				(0.05)		_		0.17		
Share-based compensation expense		0.26		0.20		1.01		0.79		
Amortization of acquired intangibles		0.14		0.11		0.45		0.44		
Acquisition-related expenses		0.06		_		0.13		_		
Severance-related and other expenses		0.03		0.02		0.27		0.04		
Amortization of debt issuance costs		0.02		0.01		0.04		0.05		
Amortization of discount on convertible senior notes		0.10		_		0.11				
Tax effect of the adjustments above <sup>(b)</sup>		(0.07)		(0.03)		(0.21)		(0.11		
Non-GAAP net income per share- diluted	\$	0.91	\$	0.77	\$	2.54	\$	2.81		
	÷		<u> </u>		<u> </u>		<u> </u>			
Reconciliation of GAAP net income to non-GAAP EBITDA	(d):									
GAAP net income	\$	16,377	\$	22,095	\$	32,194	\$	61,338		
Share-based compensation expense		11.663		8,874		44,697		34.049		
Interest (income) and expense, net		(82)		(587)		360		1,378		
Depreciation and amortization expense		17,164		14,034		61,067		53,559		
Acquisition-related expenses		2,482		_		5,603				
Severance-related and other expenses <sup>(a)</sup>		1,113		795		11,949		1.715		
Amortization of debt issuance costs		843		486		1.597		2,205		
Amortization of discount on convertible senior notes		4,517		.50		4,766		2,200		
Income tax expense (benefit)		(2,501)		(125)		(2,845)		12,595		
Non-GAAP EBITDA	\$	51,576	s	45,572	\$	159,388	s	166,839		
Non-GAAP EBITDA Non-GAAP EBITDA margin (non-GAAP EBITDA % to total revenues)	Ψ	20.7%	φ	18.4%	Ψ	17.9%	φ	18.6%		

For the three months ended December31, 2020, other expenses included approximately \$0.1 million of IP and legal entities restructuring costs, and \$1.0 million of certain litigation costs. For the year ended Decembe61, 2020, other expenses included approximately \$1.0 million of IP and legal entities restructuring costs, and \$1.0 million of certain litigation costs. For the three months and year ended Decembe61, 2019, other expenses included approximately \$0.8 million and \$1.7 million of IP and legal entities restructuring costs, respirely.

Tax effects calculated for all adjustments except tax benefits and expenses, and sharbased compensation expense, using an estimated annua effective tax rate of 21% for both fiscal years 2020 and 2019.

Non-GAAP diluted shares exclude the impact of dilutive convertble senior notes for which the Company is economically hedged through its anti-dilutive convertible note hedge transaction.

Defined as earnings before interest income and expense, taxes, depreciation, amortization, sharbased compensation, as well as excluding certain non-GAAP adjustments.

